David Meeker

FDA Building

Pharma

Rhythm scores first FDA nod for rare genetic-defect obesity med

With its new FDA approval for Imcivree, Rhythm Pharmaceuticals is entering a new field of treating obesity by targeting genetic defects.

Eric Sagonowsky Nov 30, 2020 3:37am

Sanofi

NICE backflips on Sanofi's Gaucher med Cerdelga

Jun 1, 2017 9:32am

sanofi HQ

Sanofi Genzyme chief Meeker bows out, Sibold steps in

Apr 5, 2017 9:45am